调节肠-肝轴以及粪便微生物群在肝硬化中的关键作用。
Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.
作者信息
Woodhouse Charlotte, Singanayagam Arjuna, Patel Vishal C
机构信息
King's College London, London, UK and King's College Hospital NHS Foundation Trust, London, UK.
St George's University Hospitals NHS Foundation Trust, London, UK and senior clinical lecturer, St George's University of London, London, UK.
出版信息
Clin Med (Lond). 2020 Sep;20(5):493-500. doi: 10.7861/clinmed.2020-0676.
Abstract
Cirrhosis is associated with intestinal dysbiosis, with specific alterations in the gut microbiota linked to particular aetiologies and manifestations of the disease. We review the role of the gut microbiome and the importance of the intestinal barrier in cirrhosis, provide an overview of the terminology and techniques relevant to this emerging area, and discuss the latest developments in therapies targeting the gut-liver axis.
摘要
肝硬化与肠道菌群失调有关，肠道微生物群的特定改变与该疾病的特定病因和表现相关。我们回顾了肠道微生物组的作用以及肠道屏障在肝硬化中的重要性，概述了与这一新兴领域相关的术语和技术，并讨论了针对肠-肝轴的治疗方法的最新进展。
相似文献
1
Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.调节肠-肝轴以及粪便微生物群在肝硬化中的关键作用。
Clin Med (Lond). 2020 Sep;20(5):493-500. doi: 10.7861/clinmed.2020-0676.
2
Microbiota, cirrhosis, and the emerging oral-gut-liver axis.微生物群、肝硬化和新兴的口腔-肠道-肝脏轴。
JCI Insight. 2017 Oct 5;2(19):94416. doi: 10.1172/jci.insight.94416.
3
The gut-liver axis in liver disease: Pathophysiological basis for therapy.肝脏疾病中的肠-肝轴：治疗的病理生理学基础。
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
4
Promises of microbiome-based therapies.基于微生物组的治疗方法的承诺。
J Hepatol. 2022 Jun;76(6):1379-1391. doi: 10.1016/j.jhep.2021.12.003.
5
The gut microbiota-bile acid axis in cholestatic liver disease.肠肝菌-胆汁酸轴在胆汁淤积性肝病中的作用。
Mol Med. 2024 Jul 19;30(1):104. doi: 10.1186/s10020-024-00830-x.
6
Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy the gut-liver-brain axis.肠道微生物群在轻微型肝性脑病发病机制和治疗中的作用——肠道-肝脏-大脑轴。
World J Gastroenterol. 2023 Jan 7;29(1):144-156. doi: 10.3748/wjg.v29.i1.144.
7
The gut-liver axis in immune remodeling of hepatic cirrhosis.肠-肝轴在肝硬化免疫重塑中的作用。
Front Immunol. 2022 Aug 8;13:946628. doi: 10.3389/fimmu.2022.946628. eCollection 2022.
8
Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis.肠道菌群失调和小肠细菌过度生长作为肝硬化中肠道微生物群紊乱的独立形式。
World J Gastroenterol. 2022 Mar 14;28(10):1067-1077. doi: 10.3748/wjg.v28.i10.1067.
9
Altered Microbiome in Patients With Cirrhosis and Complications.肝硬化及并发症患者的肠道微生物组改变。
Clin Gastroenterol Hepatol. 2019 Jan;17(2):307-321. doi: 10.1016/j.cgh.2018.08.008. Epub 2018 Aug 9.
10
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis.肝脏疾病和肝硬化中的微生物群变化及肠道微生物群移植
J Hepatol. 2020 May;72(5):1003-1027. doi: 10.1016/j.jhep.2020.01.017. Epub 2020 Jan 28.
引用本文的文献
1
The Gut-Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics.人体内的肠-器官轴：肠道菌群失调与益生元的作用
Life (Basel). 2023 Oct 8;13(10):2023. doi: 10.3390/life13102023.
2
Alterations in the "Gut-Liver Axis" on Rats with Immunological Hepatic Fibrosis.免疫性肝纤维化大鼠“肠-肝轴”的改变。
J Immunol Res. 2023 Sep 21;2023:5577850. doi: 10.1155/2023/5577850. eCollection 2023.
3
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy.肠道微生物群的未来调控：从生态制剂到粪便微生物群移植、工程菌和噬菌体疗法。
Antibiotics (Basel). 2023 May 8;12(5):868. doi: 10.3390/antibiotics12050868.
4
Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.多糖通过调控肠-肝轴对非酒精性脂肪性肝病治疗作用的研究进展。
Int J Mol Sci. 2022 Oct 3;23(19):11710. doi: 10.3390/ijms231911710.
5
Effects of Previous Kasai Surgery on Gut Microbiota and Bile Acid in Biliary Atresia With End-Stage Liver Disease.既往葛西手术对终末期肝病型胆道闭锁患儿肠道微生物群和胆汁酸的影响
Front Med (Lausanne). 2021 Sep 27;8:704328. doi: 10.3389/fmed.2021.704328. eCollection 2021.
本文引用的文献
1
Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis.粪便细胞因子谱作为急性失代偿期肝硬化肠道炎症的标志物
JHEP Rep. 2020 Dec;2(6):100151. doi: 10.1016/j.jhepr.2020.100151. Epub 2020 Jul 30.
2
Antimicrobial resistance in chronic liver disease.慢性肝病中的抗菌药物耐药性。
Hepatol Int. 2020 Jan;14(1):24-34. doi: 10.1007/s12072-019-10004-1. Epub 2019 Dec 3.
3
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.噬菌体靶向肠道细菌可减轻酒精性肝病。
Nature. 2019 Nov;575(7783):505-511. doi: 10.1038/s41586-019-1742-x. Epub 2019 Nov 13.
4
Drug-Resistant Bacteremia Transmitted by Fecal Microbiota Transplant.耐药菌血症通过粪便微生物群移植传播。
N Engl J Med. 2019 Nov 21;381(21):2043-2050. doi: 10.1056/NEJMoa1910437. Epub 2019 Oct 30.
5
The gut-liver axis in liver disease: Pathophysiological basis for therapy.肝脏疾病中的肠-肝轴：治疗的病理生理学基础。
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
6
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.肠道微生物群驱动的肠道血管屏障破坏是非酒精性脂肪性肝炎发展的前提。
J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
7
Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.肝硬化中固有免疫功能障碍的原因和后果。
Front Immunol. 2019 Feb 25;10:293. doi: 10.3389/fimmu.2019.00293. eCollection 2019.
8
Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent infection.微生物胆汁盐水解酶介导粪菌移植治疗复发性感染的疗效。
Gut. 2019 Oct;68(10):1791-1800. doi: 10.1136/gutjnl-2018-317842. Epub 2019 Feb 11.
9
PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial.PROFIT：一项前瞻性、随机、安慰剂对照的粪便微生物群移植治疗肝硬化的可行性试验：一项单盲试验的研究方案。
BMJ Open. 2019 Feb 15;9(2):e023518. doi: 10.1136/bmjopen-2018-023518.
10
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.全球肝硬化患者细菌感染的流行病学和影响。
Gastroenterology. 2019 Apr;156(5):1368-1380.e10. doi: 10.1053/j.gastro.2018.12.005. Epub 2018 Dec 13.
Zotero 插件